Please login to the form below

Not currently logged in
Email:
Password:

Cephalon to buy cancer drug developer

Cephalon has entered into an agreement to acquire the cancer drug development company Gemin X Pharmaceuticals in a deal that could be worth up to $525m

Cephalon has entered into an agreement to acquire the privately held cancer drug development company Gemin X Pharmaceuticals in a deal that could be worth up to $525m.

The deal calls for Cephalon to pay $225m upfront plus up to $300m in potential payments tied to regulatory and sales milestones. However, Cephalon is not obligated to pay royalties on products that eventually make it to market.

Gemin X, which is based in Pennsylvania and has research operations in Montreal, Canada, was founded in 1998 as a spin-out of Canada's McGill University. The company is focused on developing cancer therapies that re-initiate programmed forms of cell death, including apoptotic and autophagic cell death, and inhibit metabolism in cancerous cells.

Gemin X's lead product is a phase IIb small cell lung cancer drug known as obatoclax, which the company hopes will win approval as a first-line treatment in combination with chemotherapy. Enrollment in the phase IIb trial was completed in November 2009, and the company plans to present the full data from the study at upcoming scientific meetings. The drug has also shown pre-clinical and clinical activity as a single agent and in combination with standard therapies for a number of other types of cancer, the company said.

The acquisition deal is expected to close in the second quarter of 2011, after which Gemin X will operate as a wholly-owned subsidiary of Cephalon.

The deal comes on the heels of two other recent acquisitions of drug development companies by Cephalon intended to diversify its offerings. Last year, the company bought Ception after the privately held company announced positive phase II results for a humanised monoclonal antibody intended to treat asthma. In 2009, Cephalon acquired Arana Therapeutics, an Australian company with a protein engineering technology platform for turning proteins, including antibodies, into drug candidates.

22nd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics